Compare HRTG & CBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | HRTG | CBIO |
|---|---|---|
| Founded | 2012 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 670.9M | 537.5M |
| IPO Year | 2014 | 2013 |
| Metric | HRTG | CBIO |
|---|---|---|
| Price | $34.42 | $19.26 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 6 |
| Target Price | ★ $33.50 | $26.67 |
| AVG Volume (30 Days) | 232.5K | ★ 242.1K |
| Earning Date | 05-07-2026 | 04-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 214.43 | N/A |
| EPS | ★ 3.23 | N/A |
| Revenue | ★ $847,330,000.00 | $18,500.00 |
| Revenue This Year | $7.50 | N/A |
| Revenue Next Year | $6.74 | $279.20 |
| P/E Ratio | $10.54 | ★ N/A |
| Revenue Growth | ★ 3.71 | N/A |
| 52 Week Low | $20.48 | $8.72 |
| 52 Week High | $36.50 | $27.41 |
| Indicator | HRTG | CBIO |
|---|---|---|
| Relative Strength Index (RSI) | 59.15 | 57.80 |
| Support Level | $25.34 | $16.65 |
| Resistance Level | $36.06 | $21.14 |
| Average True Range (ATR) | 1.03 | 1.31 |
| MACD | -0.22 | 0.25 |
| Stochastic Oscillator | 43.11 | 54.44 |
Heritage Insurance Holdings Inc is a regional property and casualty insurance company that offers a variety of personal and commercial insurance products. Through its subsidiaries, Heritage Property & Casualty Insurance, Narragansett Bay Insurance, and Zephyr Insurance, the company issues personal residential property insurance across various states in the U.S. It also offers commercial residential insurance predominantly for its Florida properties. Heritage Insurance manages insurance underwriting, customer services, actuarial analysis, distribution, and claims processing internally. The company operates in Alabama, California, Connecticut, Delaware, Florida, Georgia, Hawaii, Maryland, Massachusetts, Mississippi, New Jersey, New York, North Carolina, Rhode Island, and South Carolina.
Crescent Biopharma Inc is a biopharmaceutical company developing novel therapeutics to treat solid tumors, led by CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody. Crescent's pipeline product CR-001 has the potential to deliver improved clinical efficacy and safety over pembrolizumab. CR-001 is a new molecular entity designed to replicate the functional properties of ivonescimab, a cooperative bispecific anti-PD-1/anti-VEGF antibody in development by Akeso Biopharma and Summit Therapeutics that delivered improved efficacy in a head-to-head Phase 3 clinical trial versus Keytruda in non-small cell lung cancer. The company focuses on advancing its second and third programs, CR-002 and CR-003, which are antibody drug conjugates (ADCs) against validated oncology targets.